AbCellera-discovered antibody granted interim authorization by health Canada as a treatment for COVID-19

▴ AbCellera-discovered antibody granted interim authorization by health Canada as a treatment for COVID-19
Bamlanivimab received emergency use authorization (EUA) from the U.S. Food and Drug Administration on November 9, 2020

AbCellera announced that bamlanivimab a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company, was granted authorization by Health Canada under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Bamlanivimab, which has been shown in clinical trials to reduce viral load, symptoms, and hospitalizations, is authorized for the treatment of adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and who are at high risk of progressing to severe COVID-19 illness and/or hospitalization. Details regarding the interim authorization can be found here.

“As a Canadian company, we are proud to contribute to the global fight against COVID-19 and hope our efforts will help people in Canada and around the world in the face of this medical emergency,” said Carl Hansen, Ph.D., CEO of AbCellera. “We applaud Lilly for bringing bamlanivimab to patients at record speed and its commitment to ensuring treatment access for patients with high unmet needs, no matter where they live.”

Bamlanivimab received emergency use authorization (EUA) from the U.S. Food and Drug Administration on November 9, 2020. Both the Canadian interim authorization and American EUA are based on data from BLAZE-1, a randomized, double-blind placebo-controlled Phase 2 study in patients with recently diagnosed mild to moderate COVID-19 in the outpatient setting. Bamlanivimab was the first monoclonal antibody therapy for COVID-19 to enter human testing in the United States and is currently undergoing multiple Phase 1, 2, and 3 clinical trials. Bamlanivimab was discovered from the blood of a recovered COVID-19 patient by AbCellera, scientists at the Vaccine Research Center at National Institute of Allergy and Infectious Diseases (NIAID) and Lilly.

AbCellera’s COVID-19 response was based on capabilities developed over the past two years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of P3 is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.

Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

Tags : #AbCellera #LatestNewsonAbCellera23rdNov #EliLilly #LatestNewsonEliLilly23rdNov #LatestPharmaCollaboration23rdNov #LatestNewsonCOVIDTreatment23rdNov #LatestPharmaNews23rdNov #USFDA #EUA #USA #HealthCanada

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Traditional Medicine Goes Global: How Ayush 2024 Reimagined WellnessDecember 26, 2024
Aster Guardians Global Nursing Award 2025 worth INR 2 Crore now open for nominations worldwide December 26, 2024
Holiday Season Round the Corner? 6 Daily Habits That Could Be The Reason Behind Your Fatty LiverDecember 26, 2024
Healing the Nation: Doctors as Architects of a Healthier FutureDecember 26, 2024
Brewing Health Benefits: Can Coffee and Tea Help Fight Head and Neck Cancers?December 26, 2024
Seven-Year-Old Fights Back Against Rare Autoimmune DiseaseDecember 26, 2024
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive YearDecember 26, 2024
American Oncology Institute (AOI) in Nagpur Restores Mobility with KyphoplastyDecember 26, 2024
Sanjeevani Healthcare & Wellness Expo 2024: A Dynamic Platform for Global Healthcare CollaborationDecember 23, 2024
Ranitidine: Saviour or Suspect? The Truth Behind the Stomach Acid RemedyDecember 23, 2024
From One-Size-Fits-All to Precision Medicine: The New Hope for Rare Bone Cancer PatientsDecember 23, 2024
World Meditation Day: India’s Gift of Peace to a Chaotic WorldDecember 23, 2024
Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and TreatmentDecember 23, 2024
Black Angels remind us of centuries of injustices plaguing the TB responseDecember 20, 2024
Healthcare Startups to Watch Out for in 2025December 20, 2024
Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in IndiaDecember 20, 2024
The Future of Malaria Prevention: Can This Vaccine Eliminate the Disease?December 20, 2024
Why the World Trusts Indian Pharmaceuticals for Life-Saving SolutionsDecember 20, 2024
International Tsunami Conference Concludes at AmritapuriDecember 20, 2024
Prestige Marks 75 Years of Revolutionizing Home Cooking with Iconic Innovative ProductsDecember 20, 2024